| Sep 20 |
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
|
| Sep 20 |
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
|
| Sep 19 |
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
|
| Sep 18 |
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
|
| Sep 17 |
Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants
|
| Sep 16 |
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
|
| Sep 16 |
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
|
| Sep 16 |
Sanofi: Information concerning the total number of voting rights and shares - August 2024
|
| Sep 16 |
Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA
|
| Sep 16 |
Sanofi readies to meet US demand for RSV antibody
|
